For Forest Labs, Inc, Deals Are Coming Fast And Furiex

Acquiring Furiex and its highly complementary IBS drug looks like a very good deal for Forest Labs.

Apr 28, 2014 at 6:30PM

This is definitely a season of deals in the health care space, with Forest Labs (NYSE:FRX) choosing to add another asset to its GI business ahead of its anticipated merger with Actavis (NYSE:AGN). Forest Labs is offering a significant premium for Furiex Pharmaceuticals (UNKNOWN:FURX.DX) and there are still FDA-related risks in play, but it seems like a reasonable offer for what could prove to be a highly synergistic asset.

The deal to be
Assuming all of the relevant i's are dotted and t's crossed, Forest Labs will acquire Furiex for $95 per share in cash, or $1.1 billion. Forest will offset the cost of the deal through an agreement to sell Furiex's royalty streams on alogliptin and Priligy to Royalty Pharma for $315 million after tax.

Forest Labs is also offering very important contingent value rights (or CVR) to Furiex shareholders. Depending upon if and/or how the FDA treats Furiex's lead drug eluxadoline as a controlled substance, shareholders could receive an additional $30 per share in cash (no scheduling), $20 (Schedule 5), or $10 (Schedule 4).

Why do the deal?
This deal makes a tremendous amount of sense for Forest Labs. Furiex is basically a drug development specialist with a single high-profile asset – eluxadoline for the treatment of diarrhea-predominant irritable bowel syndrome (or IBS-D). Furiex reported solid topline phase 3 data back in February, announcing that eluxadoline led to significantly better response rates (stool consistency and pain) in comparison to placebo; in study 3002, response rates were in the very high 20%'s over weeks one to 12 and the low 30%'s from weeks one to 26 versus placebo response rates of 16% and 20%, respectively.

There is a risk that the FDA will schedule eluxadoline as a controlled substance (it is an agonist of the mu and delta opioid receptors). Being placed on Schedule Four or Five would create some limitations regarding prescriptions and would impose some additional burdens on prescribing physicians and pharmacists, the net effect of which would likely be to reduce the number of patients taking the drug and its overall revenue potential.

Even so, exluxadoline looks like a highly complementary drug for Forest Labs. The company already markets Linzess through its partnership with Ironwood Pharmaceuticals. Linzess is approved for constipation-predominant IBS (IBS-C) and it will likely take only the most minimal incremental efforts to add eluxadoline to this sales effort. As the same doctors generally treat both types of IBS, it should make the sales calls of Forest reps incrementally more productive and profitable.

Based on my reading of Furiex's 10-K, Forest/Furiex will owe milestone payments to Johnson & Johnson if and when the drug is approved in the U.S. and if the drug hits certain milestones. Forest/Furiex will also owe a royalty up into the high single digits on exluxadoline sales.

A reasonable deal
Furiex has not yet filed for FDA approval, but expects to do so in the third quarter of 2014. The FDA has given a hard time to other IBS drugs in the past, including Salix Pharmaceuticals' Xifaxan, but the phase 3 results that Furiex announced in February should de-risk the approval process pretty significantly.

Assuming a best case scenario (no scheduling), Forest will be paying close to $1.5 billion for Furiex, or about $1.2 billion net of the royalty sales. Given estimates of the IBS-D market being worth $400 million to $600 million a year, that seems like a very attractive price for Forest. Forest Labs could perhaps see a competitive counter-bid, but rival bidders would need a pre-exisitng GI sales force to really make the numbers work and there are only a limited number of plausible bidders. It's also worth noting that this bid really isn't dependent upon the Actavis transaction going through; the arguments for acquiring Furiex and eluxadoline would hold up even if the Actavis deal fell through.

The bottom line

It's a little surprising that Forest was able to get this asset for such a seemingly reasonable price, though the risk of exluadoline being declared a Schedule Four drug is a significant one in terms of potential sales ramifications. While Furiex shareholders may hope a better offer comes through (and should probably hold their shares for a little while to see if a bid materializes), competing bids aren't all that common in the drug space.

Looking for the next big thing in health care? Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology’s true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information